CompletedPhase 2

Valchlor in the Treatment of Lichen Planopilaris

United States12 participantsStarted 2018-04-01

Plain-language summary

The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients 18 years or older. * Biopsy proven diagnosis of Lichen Planopilaris * Biopsy proven diagnosis of Fontal Fibrosing Alopecia (a clinical variant of LPP restricted to frontal scalp) * Good general health as confirmed by medical history * Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and * Patients who read and sign an approved informed consent for this study Exclusion Criteria: * Vulnerable study population * Pregnant or nursing women * Women planning a pregnancy within the study period * Active smokers * Known history of adverse reaction to mechlorethamine * Use of systemic immunosuppressive * Presence of ulcerated scalp lesions

What they're measuring

Change in Lichen Planopilaris Activity Index (LLPAI)

Timeframe: baseline, up to 24 weeks

Trial details

NCT IDNCT03417141

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-30

Results submitted2020-06-01

View on ClinicalTrials.gov More Lichen Planopilaris trials